JMPWA
TCRR

JP Morgan Private Wealth Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,616
Closed -$46K – 2019
2022
Q3 		$46K Hold
25,616
– – ﹤0.01% 1897
2022
Q2 		$74K Hold
25,616
– – ﹤0.01% 1885
2022
Q1 		$71K Hold
25,616
– – ﹤0.01% 1959
2021
Q4 		$119K Buy
+25,616
New +$160K ﹤0.01% 1937

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Private Wealth Advisors's TCRR Position: Q4 2022 in Review

JP Morgan Private Wealth Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 25,616 shares — an estimated $46K sold.

JP Morgan Private Wealth Advisors first reported a position in TCRR in Q4 2021 and held it in 4 quarters. The position peaked at $119K in Q4 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • JP Morgan Private Wealth Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 25,616 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $46K.
  • JP Morgan Private Wealth Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • JP Morgan Private Wealth Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $119K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.